189 filings
8-K
MRKR
Marker Therapeutics Inc
12 Jun 24
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
MRKR
Marker Therapeutics Inc
15 May 24
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
4:40pm
8-K
MRKR
Marker Therapeutics Inc
8 Apr 24
Other Events
7:09am
8-K
MRKR
Marker Therapeutics Inc
25 Mar 24
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
6:18pm
8-K
MRKR
Marker Therapeutics Inc
1 Mar 24
Termination of a Material Definitive Agreement
8:02am
8-K
9hle2jgde xr6svl8j7p
26 Feb 24
Entry into a Material Definitive Agreement
7:58am
8-K
m2g5awl35p
8 Jan 24
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
8:30am
8-K
t46n nvgrffqegfw
11 Dec 23
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
7:35am
8-K
rv6tphl2mgfhg9ob
20 Nov 23
Departure of Directors or Certain Officers
4:37pm
8-K
jmmzfh6a64fmxho
9 Nov 23
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
5:03pm
8-K
6bxbo2
11 Sep 23
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
7:10am
8-K
4jllmhzj x522tm918
14 Aug 23
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:37pm
8-K
89w4 9k0qlvkkkd4bqf
7 Aug 23
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
7:22am
8-K
ea4mdny9cf
10 Jul 23
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
7:09am
8-K
66ifdo2pg75etd
3 Jul 23
Departure of Directors or Certain Officers
4:05pm
8-K
vk73qqzoba 9xxft
30 Jun 23
Completion of Acquisition or Disposition of Assets
4:05pm
8-K
lqlv25owdpgwwwwb8
26 Jun 23
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
7:14am
8-K
9axvjmym
12 Jun 23
Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial
7:09am
8-K
04rb7p acz
9 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
abbcr3y7enzmltifji
31 May 23
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells
6:44am